Cytokines, Chemokines & Receptors

Cat. No.

AT0884

CAS No.

2648456-30-6

Galvokimig

Synonyms: UCB-9741

Galvokimig is a monoclonal antibody designed to target and neutralize interleukin 13 (IL-13), interleukin 17A (IL-17A), albumin (ALB), and interleukin 17B (IL-17B). This antibody is engineered for high specificity and affinity, making it suitable for use in research studies investigating the roles and interactions of these cytokines in various inflammatory and autoimmune conditions. Galvokimig can be applied in a range of experimental setups, including immunoassays, functional studies, and as a potential therapeutic strategy model.

Cat. No.

AT0892

CAS No.

1791411-57-8

Lutikizumab

Synonyms: ABT-981

Lutikizumab (ABT-981) is a dual variable domain immunoglobulin designed to specifically target and inhibit both interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β). This monoclonal antibody functions by binding to these cytokines, effectively neutralizing their activity and mitigating their pro-inflammatory effects. Lutikizumab is primarily utilized in research focused on understanding and treating osteoarthritis, providing a valuable tool for investigating the role of IL-1 in inflammatory processes associated with this degenerative disease.

Cat. No.

AT0964

CAS No.

428863-50-7

Certolizumab pegol

Synonyms: Certolizumab; CDP870

Certolizumab pegol is a recombinant, polyethylene glycolylated antigen-binding fragment derived from a humanized monoclonal antibody. It selectively targets and neutralizes tumor necrosis factor-alpha (TNF-α), making it highly relevant for studies in rheumatoid arthritis and Crohn's disease. This specificity for TNF-α provides a critical tool for researchers investigating the pathophysiology and therapeutic interventions of these inflammatory disorders.

Cat. No.

AT0973

CAS No.

3018901-76-0

Arumakimig

Arumakimig is a bispecific humanized antibody designed to target and neutralize both interleukin-18 (IL-18) and interleukin-1β (IL-1β). This dual specificity makes it an invaluable tool for research focused on inflammation and immune response modulation. Arumakimig is particularly suited for studies investigating the pathophysiology of diseases characterized by excessive or dysregulated inflammation, offering insights into potential therapeutic interventions.

Cat. No.

AT1052

CAS No.

1143503-69-8

Ixekizumab

Synonyms: LY2439821

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody engineered to selectively bind and neutralize interleukin-17A (IL-17A) with a dissociation constant (K_D) of less than 3 pM. This antibody effectively inhibits the interaction of IL-17A with its receptor, IL-17RA, without interacting with other members of the IL-17 cytokine family. Ixekizumab is primarily utilized in research focused on the pathophysiology and treatment of moderate-to-severe plaque psoriasis.

Cat. No.

AT1128

CAS No.

272780-74-2

Metelimumab

Synonyms: CAT-192; Anti-TGFB1 Recombinant Antibody

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody engineered to selectively neutralize transforming growth factor beta 1 (TGFβ1). This specificity makes it a valuable tool for researchers studying fibrosis, cancer progression, and other TGFβ1-related pathologies.

Cat. No.

AT1166

CAS No.

1006877-41-3

Sifalimumab

Synonyms: MEDI-545; MDX 1103

Sifalimumab (MEDI-545) is a monoclonal antibody that targets and neutralizes multiple subtypes of interferon-alpha (IFNα), a key cytokine involved in the pathogenesis of autoimmune disorders. By binding to IFNα, Sifalimumab effectively suppresses abnormal immune responses. This antibody is particularly relevant for research into systemic lupus erythematosus (SLE), providing a valuable tool for investigating the role of IFNα in SLE pathophysiology and for exploring potential therapeutic interventions.

Cat. No.

AT1196

CAS No.

2740565-02-8

Falbikitug

Falbikitug is a humanized IgG1-kappa monoclonal antibody targeting leukemia inhibitory factor (LIF). Classified as an antineoplastic agent, Falbikitug is designed for therapeutic applications in oncology, specifically targeting and neutralizing LIF to inhibit tumor growth and progression. This antibody may be utilized in research studies to explore the role of LIF in cancer biology and to assess its potential as a therapeutic target in various malignancies.

Cat. No.

AT1216

CAS No.

1792181-33-9

Vunakizumab

Synonyms: Anti-Human IL17A Recombinant Antibody

Vunakizumab is a recombinant human IgGκ monoclonal antibody specifically designed to target and neutralize interleukin-17A (IL-17A). By binding to IL-17A, Vunakizumab effectively prevents its interaction with the IL-17 receptor, thereby inhibiting the pro-inflammatory pathways associated with this cytokine. This antibody is particularly useful in research focused on autoimmune disorders, including psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis, where IL-17A plays a key role in disease pathogenesis.

Cat. No.

AT1225

CAS No.

2382921-73-3

Xeligekimab

Synonyms: GR 1501

Xeligekimab (GR 1501) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin 17A (IL-17A), a key cytokine involved in the induction and maintenance of pro-inflammatory responses. By binding to IL-17A, Xeligekimab effectively inhibits the cytokine's interaction with its receptor, thereby disrupting the pro-inflammatory cascade. This antibody is utilized in research focused on inflammatory diseases to understand the role of IL-17A in disease pathology and to evaluate potential therapeutic interventions.

Cat. No.

AT1268

CAS No.

2151032-62-9

Cendakimab

Synonyms: RPC 4046; ABT 308; CC-93538

Cendakimab (RPC4046; ABT 308; CC-93538) is a humanized, recombinant monoclonal antibody engineered to selectively target the interleukin-13 (IL-13) cytokine. Demonstrating high affinity and potency, this antibody effectively binds to both the wild-type and variant forms of human IL-13. Cendakimab inhibits the interaction of IL-13 with its receptors, IL-13Rα1 and IL-13Rα2, exhibiting half-maximal inhibitory concentrations (IC50s) of 352 pM and 631 pM, respectively, as determined by enzyme-linked immunosorbent assay (ELISA). Furthermore, it exhibits binding affinities of 52 pM for wild-type IL-13 and 50 pM for the R110Q polymorphic variant of IL-13. The therapeutic potential of Cendakimab spans various IL-13-mediated allergic and inflammatory conditions, including asthma and eosinophilic esophagitis.

Cat. No.

AT1348

CAS No.

1688648-13-6

Licaminlimab

Synonyms: OCS-02

Licaminlimab (OCS-02) is a single-chain antibody fragment specifically targeting TNF alpha, a pro-inflammatory cytokine predominantly secreted by macrophages and monocytes. This monoclonal antibody fragment is designed to neutralize TNF alpha, thereby modulating inflammatory responses. It is applicable in research focused on the pathophysiology and treatment of diseases characterized by excessive inflammation.

Cat. No.

AT1422

CAS No.

285985-06-0

Lerdelimumab

Synonyms: CAT-152

Lerdelimumab (CAT-152) is a recombinant human monoclonal antibody of the IgG4 subclass that specifically targets transforming growth factor-beta 2 (TGF-β2). This antibody is utilized in research as an anti-scarring agent, particularly in studies related to glaucoma. Its mechanism of action involves neutralizing the biological activity of TGF-β2, a cytokine implicated in the pathogenesis of fibrosis and scarring.

Cat. No.

AT1450

CAS No.

1401965-15-8

Bermekimab

Synonyms: MABp1

Bermekimab (MABp1) is a human monoclonal antibody designed to specifically target and neutralize interleukin-1 alpha (IL-1α). By inhibiting this cytokine, Bermekimab effectively reduces tumor-associated inflammation, offering potential therapeutic benefits in the management of cancer-related inflammatory processes.

Cat. No.

AT1455

CAS No.

1174395-19-7

Brodalumab

Synonyms: AMG 827; KHK4827

Brodalumab (AMG 827) is a humanized IgG2 monoclonal antibody targeting the interleukin-17 receptor. This antibody is utilized in research focused on understanding and treating moderate-to-severe plaque psoriasis and rheumatoid arthritis. Brodalumab's mechanism involves blocking the activity of interleukin-17 (IL-17), a cytokine that plays a critical role in mediating inflammatory and immune responses.

Cat. No.

AT1470

CAS No.

948564-73-6

Fresolimumab

Synonyms: GC1008

Fresolimumab (GC1008) is a human monoclonal antibody designed to target and neutralize all active mammalian subtypes of Transforming Growth Factor-beta (TGF-β). It exhibits a high binding affinity to TGF-β2, with a dissociation constant (Kd) of 1.8 nM, indicating robust interaction with this cytokine. When conjugated with the radiolabel 89Zr, Fresolimumab serves as a valuable tool for Positron Emission Tomography (PET) analysis, facilitating the study of TGF-β expression, antibody biodistribution, and organ-specific uptake. This antibody is extensively applicable in research focused on cancer, fibrosis, osteogenesis imperfecta, and kidney disease, providing insights into the pathophysiological roles of TGF-β in these conditions.

Cat. No.

AT1490

CAS No.

3021525-26-5

Lasrekibart

Lasrekibart is a humanized monoclonal antibody designed to selectively target human interleukin 5 (IL-5). By binding specifically to IL-5, Lasrekibart effectively blocks the interaction between IL-5 and its receptor, thereby exerting immunosuppressive and anti-inflammatory effects. This antibody is particularly valuable for research into allergic and inflammatory diseases, including asthma, offering potential insights into disease mechanisms and therapeutic avenues.

Cat. No.

AT1495

CAS No.

1476039-58-3

Nemolizumab

Synonyms: CIM331

Nemolizumab (CIM331) is a humanized monoclonal antibody designed to selectively target the interleukin-31 receptor alpha (IL-31RA). By binding to IL-31RA, Nemolizumab effectively inhibits the interaction between interleukin-31 (IL-31) and its receptor, thereby blocking the downstream signaling pathways. This inhibition is clinically relevant as it contributes to the reduction of pruritus (itching) and sleep disturbances associated with various dermatological conditions, including atopic dermatitis (AD). Nemolizumab is currently under investigation for its therapeutic potential and efficacy in treating symptoms of AD and related conditions.

Cat. No.

AT1505

CAS No.

241473-69-8

Reslizumab

Synonyms: Sch 55700

Reslizumab (Sch 55700) is a humanized monoclonal antibody designed to specifically target and neutralize interleukin-5 (IL-5), a key cytokine involved in the pathogenesis of eosinophilic asthma. This antibody exhibits a high binding affinity for human IL-5, demonstrating dissociation constants (K_D) of 109 pM and 4.3 pM in Biacore surface plasmon resonance and Kinetic Exclusion Assay analyses, respectively. By inhibiting the activity of IL-5, Reslizumab effectively reduces the growth and survival of eosinophils, thereby mitigating the inflammatory processes associated with eosinophilic asthma. This makes Reslizumab a critical tool in the therapeutic management of this condition.

Cat. No.

AT1525

CAS No.

196078-29-2

Mepolizumab

Synonyms: SB 240563

Mepolizumab (SB 240563) is a humanized monoclonal antibody designed to specifically bind to and neutralize interleukin-5 (IL-5). IL-5 is a critical cytokine that regulates eosinophil proliferation, activation, and survival. This antibody is utilized in research focused on eosinophilic conditions, including eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for these diseases.

Cat. No.

AT1535

CAS No.

1416147-64-2

Dapirolizumab

Dapirolizumab is a monoclonal antibody specifically designed to target and bind to CD40 ligand (CD40L), effectively blocking its interaction with CD40 receptors on the surface of immune cells. This interaction is crucial for the activation of the adaptive immune response. By inhibiting this pathway, Dapirolizumab helps to modulate immune system activity and has been shown to attenuate the symptoms of systemic lupus erythematosus. This antibody is applicable in research focused on the pathogenesis and treatment of autoimmune diseases, particularly those involving aberrant CD40-CD40L signaling.

Cat. No.

AT1546

CAS No.

909875-08-7

Enokizumab

Synonyms: MEDI-528

Enokizumab (MEDI-528) is a monoclonal antibody specifically designed to target interleukin-9 (IL-9). IL-9 plays a critical role in regulating various pathological processes in the respiratory system, including airway inflammation, mucus production, airway hyperresponsiveness, and fibrosis. This regulation is primarily mediated through the proliferation and activation of mast cells within the airways. Enokizumab's mechanism of action focuses on neutralizing IL-9, thereby potentially mitigating its effects on these respiratory conditions. This antibody is pivotal for research focused on the pathophysiology of respiratory diseases and the development of targeted therapies.